Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers
- Conditions
- Migraine
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT04969497
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT04066023
- Locations
- 🇺🇸
Keck Medicine of USC, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸California Medical Clinic for Headache, Santa Monica, California, United States
A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
- Conditions
- Migraine
- Interventions
- Drug: M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches)Drug: M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups)Drug: M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT03978403
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
- Conditions
- Migraine
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT03708744
- Locations
- 🇺🇸
Hill Top Research, Inc., Neptune, New Jersey, United States
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
- Conditions
- Migraine
- Interventions
- Drug: M207 Microneedle System
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Zosano Pharma Corporation
- Target Recruit Count
- 342
- Registration Number
- NCT03282227
- Locations
- 🇺🇸
Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸Elite Clinical Studies, Phoenix, Arizona, United States
🇺🇸Downtown L.A. Research Center, Los Angeles, California, United States
- Prev
- 1
- 2
- Next
News
Microneedle Technology Emerges as Game-Changer for Targeted Drug Delivery and Vaccine Administration
Microneedle technology is revolutionizing drug delivery by offering a minimally invasive alternative to traditional injection methods, with applications spanning vaccines, biologics, and gene therapies.